GlassScriptPhysician profile
Bridgette S Hampton
NPI 1982625851
$2,974.41
in general payments reported to CMS, 2019-2025
24 companies · $346 in 2025
The $346 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131 · 2020: $30.62 · 2021: $481 · 2022: $431 · 2023: $577 · 2024: $979 · 2025: $346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,901.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,901.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $641.57 | 2021-2025 | |
| Novo Nordisk INC | $337.01 | 2019-2024 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $239.03 | 2021-2025 | Airsupra, Breztri, Bevespi Aerosphere |
| Lilly USA, LLC | $191.60 | 2023-2025 | Mounjaro, Zepbound |
| Abbott Laboratories | $171.15 | 2019-2024 | Freestyle Libre 3 |
| Pfizer INC. | $170.76 | 2021-2025 | |
| Glaxosmithkline, LLC. | $158.58 | 2020-2025 | Trelegy Ellipta, Arexvy |
| Nevro Corp. | $155.92 | 2022-2023 | Senza |
| Exact Sciences Corporation | $144.11 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boston Scientific Corporation | $121.31 | 2024 | Rezum Generator |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.94 | 2023-2025 | Jardiance, Synjardy, Tradjenta |
| Amgen INC. | $110.87 | 2023-2025 | Repatha, Otezla, Otezla |
| Astellas Pharma US INC | $95.53 | 2024-2025 | Veozah |
| Idorsia Pharmaceuticals US INC | $87.00 | 2023-2024 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $55.44 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.83 | 2025 | Caplyta |
| Xeris Pharmaceuticals, INC. | $23.04 | 2024 | Gvoke Hypopen |
| E.R. Squibb & Sons, L.L.C. | $20.17 | 2024 | Eliquis |
| Allergan, INC. | $19.14 | 2020 | |
| Merck Sharp & Dohme LLC | $18.18 | 2023 | Belsomra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.64 | 2024 | Xifaxan |
| Dexcom, INC. | $16.30 | 2021 | |
| Paratek Pharmaceuticals, INC. | $13.70 | 2025 | Nuzyra |
| Athena Bioscience, LLC | $13.59 | 2023 | Nexiclon Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridgette Hampton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.